Table 2.
The result of the baseline characteristics.
| Interventions | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Study ID | Country/region | No patients (T/C) | Ejection fraction (%) | Average age (years) | Male ratio (%) | T | C | Follow-up time (months) | Outcome |
| PARADIGM-HF 2014 [10] | 47 countries | 4187/4212 | 29.5 ± 6.2 | 63.8 ± 11.4 | 78.2 | LCZ696 | Enalapril | 27 | |
| PIONEER-HF 2019 [11] | America | 440/441 | 24.5 ± 5.5 | 62.0 ± 9.5 | 72.0 | Sacubitril/Valsartan | Enalapril | 2 | |
| CURRENT 2019 [12] | Taiwan | 466/466 | 27.2 ± 7.0 | 61.8 ± 14.9 | 74.4 | Sacubitril/Valsartan | Blank | 15 | |
| PRIME 2019 [13] | Korea | 60/58 | 33.8 ± 7.2 | 62.6 ± 11.0 | 61.1 | Sacubitril/Valsartan | Valsartan | 12 | |
| PARAMOUNT 2012 [14] | 13 countries | 149/152 | 58.0 ± 7.7 | 71.0 ± 9.2 | 43.5 | LCZ696 | Valsartan | 9 | |
| PARAGON-HF 2019 [15] | 43 countries | 2407/2389 | 57.6 ± 8.0 | 72.8 ± 8.4 | 48.3 | Sacubitril/Valsartan | Valsartan | 9 | |
| EVALUATE-HF 2019 [16] | America | 231/233 | 33.5 ± 10.0 | 67.3 ± 9.2 | 76.5 | Sacubitril/Valsartan | Enalapril | 3 | |
| DEFINE-HF 2019 [17] | America | 131/132 | 26.5 ± 8.1 | 61.3 ± 11.5 | 73.3 | Dapagliflozin | Placebo | 3 | |
| DAPA-HF 2019 [18] | 20 countries | 2373/2371 | 31.1 ± 6.8 | 66.3 ± 10.9 | 76.6 | Dapagliflozin | Placebo | 18 | |
| DECLARE-TIMI 58 2019 [19] | 33 countries | 852/872 | - | 64.0 ± 6.8 | 62.6 | Dapagliflozin | Placebo | 50 | |
| EMPIRE HF 2020 [20] | Denmark | 95/95 | 30.0 ± 5.0 | 63.5 ± 8.0 | 85.0 | Empagliflozin | Placebo | 3 | |
| EMPEROR-REDUCED 2020 [21] | 20 countries | 1863/1867 | 27.5 ± 6.0 | 66.8 ± 11.0 | 76.0 | Empagliflozin | Placebo | 16 | |
| EMPEROR-PRESERVED 2021 [22] | 23 countries | 2997/2991 | 54.3 ± 8.8 | 71.9 ± 9.6 | 55.4 | Empagliflozin | Placebo | 26 | |
| SOCRATES-REDUCED 2015 [23] | Europe, North America and Asia | 91/92 | 29.0 ± 8.4 | 68 ± 12.5 | 82.0 | Vericiguat | Placebo | 4 | |
| LEPHT 2013 [24] | 18 countries | 67/69 | 27.8 ± 0.7 | 59.1 ± 12.0 | 85.0 | Riociguat | Placebo | 4 | |
| VICTORIA 2020 [25] | 42 countries | 2526/2524 | 28.9 ± 8.3 | 67.4 ± 12.2 | 76.0 | Vericiguat | Placebo | 11 | |
| SOCRATES-PRESERVED 2017 [26] | Europe, North America and Asia | 96/93 | 56.5 ± 61.0 | 73.5 ± 9.5 | 52.4 | Vericiguat | Placebo | 4 | |
C = control group, T = test group; <inline-graphic xlink:href="fx1"/> heart failure rehospitalization rate; <inline-graphic xlink:href="fx2"/> all-cause mortality; <inline-graphic xlink:href="fx3"/> cardiovascular mortality; <inline-graphic xlink:href="fx4"/> rates of cardiovascular death or heart failure rehospitalization; <inline-graphic xlink:href="fx5"/> KCCQ score; <inline-graphic xlink:href="fx6"/> NT-proBNP.